ClinicalTrials.gg
CompletedNCT07221084Updated Mar 11, 2026

A Study to Assess Pharmacokinetics, Safety, and Tolerability of Atumelnant in Healthy Japanese and Caucasian Participants

A Phase 1 interventional study of Atumelnant and Placebo in Healthy Volunteers, sponsored by Crinetics Pharmaceuticals Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-11.

Sponsored by Crinetics Pharmaceuticals Inc. (part of Vertex Pharmaceuticals Incorporated) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
21
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The purpose of this study is to assess the PK profile, safety, and tolerability of atumelnant after single and multiple once daily (QD) oral doses in healthy Japanese and Caucasian adult participants.

Read the detailed description

This is a Phase 1, stratified randomized, double-blind, placebo-controlled, 2-cohort, 2-period, fixed-sequence study to assess the PK profile, safety, and tolerability of atumelnant after single and multiple QD oral doses in healthy Japanese and Caucasian adult participants.

Approximately 20 healthy male and female participants of either Japanese or Caucasian ethnicities will be enrolled in the study to receive the study intervention.

02

Conditions studied

  • Healthy Volunteers

Keywords

  • Healthy Volunteers
  • CRN04894
  • Atumelnant
03

In context

Lead sponsor

Crinetics Pharmaceuticals Inc. is the lead sponsor of 19 studies on the registry; 3 are open to participants now.

Of its 12 completed or terminated interventional studies of FDA-regulated products, 6 (50%) have results posted.

First submitted before Crinetics Pharmaceuticals Inc. became part of Vertex Pharmaceuticals Incorporated.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male or female participants, 18 to 55 years old, inclusive, at the Screening Visit.
  • Healthy status as defined by the absence of evidence of any , in the opinion of the Investigator, active or chronic disease following a detailed medical and surgical history, a complete physical examination including vital signs, 12-lead (ECG), hematology, clinical chemistry, coagulation, serology, and urinalysis. The tests may be repeated once at Screening and at admission on Day -1 if necessary and deemed appropriate by the Investigator or designee.
  • (BMI) between 18.0 and 30.0 kg/m2, inclusive, at the Screening Visit and at admission on Day -1.
  • Meeting the criteria at the time of consent for one of the following ethnic groups:
  • Japanese participants must have been born in Japan to parents and grandparents of Japanese ethnic descent as evidenced by verbal confirmation and documented in a self-reported family tree form, have lived less than 10 years outside of Japan, and have no significant change in lifestyle, including diet, since leaving Japan.
  • Caucasian participants must be considered White of European descent.
  • Participant has a peak 30- or 60-minute ACTH stimulated serum cortisol ≥18 μg/dL during 250 μg high-dose ACTH/cosyntropin stimulation test conducted at Screening.
  • Participant has normal morning serum cortisol collected at approximately 08:00 AM (±2 hours) at admission on Day -1 and does not have signs and symptoms of adrenal insufficiency as deemed by the Investigator or designee.

Exclusion criteria

Exclusion Criteria:

  • Participant is breastfeeding or has a positive serum pregnancy test at Screening or at admission on Day -1.
  • Participant has a blood loss ≥500 mL or donated blood within 3 months prior to admission on Day -1.
  • Participant has received atumelnant previously or has previously been enrolled in this clinical study.
  • Participant has received any drug within the past 30 days or 5 half lives, whichever is longer, prior to the first dose of study intervention on Day 1.
  • Participant is unwilling to refrain from strenuous, unaccustomed exercise and sports, defined as greater than 30 minutes per day, 3 days prior to admission on Day -1.
  • Participant has history of to study intervention or any of the or to medicinal products with similar chemical structures.
  • Participant has used any prescription medication without approval of the Investigator or designee within 14 days prior to admission on Day -1. By exception, hormonal are permitted throughout the study and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines are allowed up to 14 days prior to admission on Day -1.
  • Venous access considered inadequate for sample collection.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
21 participants (actual)

Study arms

  • Experimental
    Treatment (Cohort 1)

    Fixed-sequence cohort for Japanese participants.

    Drug: Atumelnant

  • Active comparator
    Placebo (Cohort 1)

    Fixed-sequence cohort for Japanese participants.

    Drug: Placebo

  • Experimental
    Treatment (Cohort 2)

    Fixed-sequence cohort for Caucasian participants.

    Drug: Atumelnant

  • Active comparator
    Placebo (Cohort 2)

    Fixed-sequence cohort for Caucasian participants.

    Drug: Placebo

Interventions

  • Atumelnant, tablets, once daily by mouth

    Also known as: CRN04894

  • DrugPlacebo

    Placebo, tablets, once daily by mouth

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics (Cmax)

    Assessment of the maximum observed plasma concentration of atumelnant

    Time frame: [Time Frame: Up to Day 30]

  2. Pharmacokinetics (Tmax)

    Assessment of time to maximal atumelnant concentration (Tmax)

    Time frame: [Time Frame: Up to Day 30]

  3. Pharmacokinetics (AUC)

    Assessment of the plasma area under the curve of Atumelnant

    Time frame: [Time Frame: Up to Day 30]

Secondary outcomes

  1. Number of participants with Treatment Emergent Adverse Events including Adverse Events of Special Interest (adrenal insufficiency)

    Time frame: [Time Frame: Up to Day 50]

  2. Number of participants with clinically significant clinical laboratory abnormalities

    Time frame: [Time Frame: Up to Day 30]

  3. Number of participants with clinically significant changes in vital signs

    Time frame: [Time Frame: Up to Day 30]

  4. Number of participants with clinically significant changes in physical exam observations

    Time frame: [Time Frame: Up to Day 30]

  5. Number of participants with clinically significant Electrocardiogram (ECG) abnormalities

    Time frame: [Time Frame: Up to Day 20]

  6. 12-lead triplicate Electrocardiogram (ECG) corrected QT interval (QTc) interval

    Time frame: [Time Frame: Up to Day 20]

07

Study locations

1 site
  • Crinetics Study Site
    Glendale, California 91206, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2025 to primary completion in Feb 2026, 3 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 22, 2025
First posted
Oct 27, 2025
StartActual
Oct 28, 2025
Primary completionActual
Feb 7, 2026
CompletionActual
Feb 27, 2026
Last update
Mar 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07221084
Responsible party
Sponsor
First posted
Oct 27, 2025
Start date
Oct 28, 2025
Primary completion
Feb 7, 2026
Completion
Feb 27, 2026
Last update
Mar 11, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Atumelnant

Start the discussion